Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume Increase – Should You Buy?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw an uptick in trading volume on Thursday . Approximately 2,318,486 shares traded hands during mid-day trading, an increase of 4% from the previous session’s volume of 2,227,500 shares.The stock last traded at $7.9750 and had previously closed at $7.22.

Wall Street Analyst Weigh In

MRVI has been the subject of several research analyst reports. Wells Fargo & Company increased their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, UBS Group reissued a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.25.

Maravai LifeSciences Stock Up 4.2%

The company has a debt-to-equity ratio of 0.49, a current ratio of 4.05 and a quick ratio of 2.98. The company has a market cap of $2.24 billion, a PE ratio of -16.62 and a beta of 0.63. The business’s 50 day moving average is $6.28 and its 200-day moving average is $4.58.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The company had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. As a group, analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current year.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel directly owned 360,767 shares in the company, valued at $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MRVI. Royal Bank of Canada raised its position in shares of Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares in the last quarter. Virtu Financial LLC acquired a new position in Maravai LifeSciences in the fourth quarter valued at approximately $34,000. Insigneo Advisory Services LLC acquired a new position in Maravai LifeSciences in the fourth quarter valued at approximately $34,000. Quantessence Capital LLC purchased a new position in Maravai LifeSciences in the third quarter valued at approximately $31,000. Finally, Stifel Financial Corp purchased a new position in Maravai LifeSciences in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.